Key result
Oral ATIQCTPC reduces tumor and thrombus weight with ~100-fold higher potency than parent compound.
Why the study?
Does oral administration of the tumor-targeting nanomedicine ATIQCTPC inhibit tumor growth and arterial-venous shunt thrombus formation in preclinical rodent models compared to parent compound ATIQC and standard controls?
Does oral administration of the tumor-targeting nanomedicine ATIQCTPC inhibit tumor growth and arterial-venous shunt thrombus formation in preclinical rodent models compared to parent compound ATIQC and standard controls?
Preclinical synthesis and validation of ATIQCTPC demonstrates a self-assembling nanomedicine that selectively releases ATIQC in tumor tissue while targeting P-selectin to simultaneously inhibit tumor growth and thrombosis at 100-fold lower doses than its parent compound.
Answers are grounded in this paper and cite their sources.
ATIQCTPC may inhibit tumors and thrombosis at low doses in rodents; leaves open translation to human therapy.
To overcome the harmful side effects, low tolerance, and undesirable outcomes of the anticancer drugs, we used ethane-1,2-diamine to bridge antitumoral ( S )-3-acetyl-4-oxo-tetrahydroindolo[2,3-a]quinolizine-6-carboxylic acid (ATIQC) and tumor-targeting d-glucuronic acid, thereby providing (6 S )-3-acetyl-4-oxo- N -(2-(3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-carboxamido)ethyl)-4,6,7,12-tetrahydroindolo[2,3-a]quinolizine-6-carboxamide (ATIQCTPC). Atomic force microscopy images visualized, that in serum, ATIQCTPC formed particles of height <81 nm. These particles effectively avoided phagocytosis of macrophages and were stable in blood circulation. Distribution analysis indicated that ATIQCTPC accumulated and released ATIQC in the tumor tissue through a targeting manner. Thus, the antitumor and the anti-thrombotic activities of ATIQCTPC were 100-fold higher than those of ATIQC, and ATIQCTPC was able to prevent cancer patients from suffering from thrombosis. Based on the observation that ATIQCTPC decreased serum tumor necrosis factor-α (TNF-α) and interleukin-8 (IL-8) in S180 mice, we hypothesized that this is the mechanism that ATIQCTPC utilized to slow tumor growth. Additionally, we observed that ATIQCTPC inhibited thrombosis by decreasing serum P-selectin of thrombotic rats. The intermolecular association and the hexamerization manner of ATIQCTPC were experimentally evidenced and correlated with the formation of the nanoparticles.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2017) studied Subcutaneous S180 sarcoma and carotid artery-jugular vein shunt thrombosis (preclinical rodent models). ATIQCTPC ((6S)-3-acetyl-4-oxo-N-(2-(3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-carboxamido)ethyl)-4,6,7,12-tetrahydroindolo[2,3-a]quinolizine-6-carboxamide) vs. Normal saline (vehicle control), ATIQC (1 μmol/kg), doxorubicin (2 μmol/kg/day IP), or aspirin (167 or 16.7 μmol/kg) was evaluated on In vivo tumor weight in S180 mice at 7 days and thrombus weight in Wistar rats after 15 minutes of arteriovenous shunt blood flow (p=<0.05 (tumor weight vs NS); <0.01 (thrombus weight vs NS)). Oral ATIQCTPC reduced tumor weight in S180 mice and thrombus weight in rats vs saline, showing 100-fold higher potency than parent compound ATIQC.
Synapse has enriched 10 related papers. Consider them for comparative context: